Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | IDE | P14735 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34464817 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL17979844 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL22766914 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL5043638 | 0.83 | SLC6A5 (0.75) | SMN1; SMN2IDESLC6A9SLC6A5PAX8 | |
| SCHEMBL9760661 | 0.82 | MAPT (0.77) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL3918537 | 0.82 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL894767 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL3836058 | 0.81 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1KDM4ELMNAIDE | |
| SCHEMBL16406345 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL14602602 | 0.80 | CNR1 (0.62) | ALDH1A1KDM4ELMNANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | SMN1; SMN2 4526/4885ALDH1A1 2382/4885KDM4E 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.